Reuters logo
BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD
November 16, 2017 / 10:33 PM / 25 days ago

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

Nov 16 (Reuters) - Theravance Biopharma Inc

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below